Assertio (ASRT) Expected to Announce Earnings on Monday

Assertio (NASDAQ:ASRT) is expected to post its Q4 2025 results after the market closes on Monday, March 16th. Analysts expect Assertio to post earnings of ($3.05) per share and revenue of $6.1990 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 16, 2026 at 4:30 PM ET.

Assertio Stock Down 0.7%

Shares of ASRT stock opened at $11.54 on Friday. Assertio has a fifty-two week low of $7.65 and a fifty-two week high of $15.15. The firm has a market capitalization of $74.09 million, a PE ratio of -2.48 and a beta of 0.73. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.43 and a current ratio of 1.58. The stock’s 50-day simple moving average is $11.49 and its 200-day simple moving average is $11.77.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ASRT. Nantahala Capital Management LLC grew its position in shares of Assertio by 4.4% in the second quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after purchasing an additional 370,311 shares during the period. Vanguard Group Inc. raised its position in shares of Assertio by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock worth $3,899,000 after purchasing an additional 41,332 shares during the last quarter. Opaleye Management Inc. purchased a new position in Assertio in the 4th quarter valued at about $2,585,000. Edgewood Management LLC acquired a new stake in Assertio in the 4th quarter worth about $975,000. Finally, Perritt Capital Management Inc boosted its holdings in Assertio by 51.6% in the 3rd quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after buying an additional 119,281 shares during the last quarter. 48.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Zacks Research lowered Assertio from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Wall Street Zen raised shares of Assertio to a “buy” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective (up from $3.00) on shares of Assertio in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Assertio has an average rating of “Hold” and a consensus price target of $35.00.

Assertio Company Profile

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.